[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neutralizing-antibodies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neutralizing-antibodies":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100619680","study-of-the-serotype-and-genotype-of-bk-virus-in-kidney-transplant-recipients-and-their-donors-to-identify-individuals-at-risk-of-nephropathy-100619680",false,"NCT07347769","Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy","TYPIK","Inclusion Criteria:\n\n* Kidney transplant patients with a first positive BK virus viral load in urine. - BK virus viral load in urine \\> 3 log copies\u002FmL.\n* More than 3 months post-transplant and less than 2 years post-transplant.\n* Men or women aged 18 years and older.\n* Followed up at Grenoble Alpes University Hospital.\n* Affiliated with social security or beneficiary of such a scheme.\n* Patients who are not opposed to the TYPIK study.\n\nExclusion Criteria:\n\n* Expected renal graft survival is \\\u003C 6 months, estimated by an eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m² at the time of BKPyV viruria\n* Patients who object to the use of their data and\u002For samples for research purposes\n* Subjects who are excluded from another study\n* Subjects under administrative or judicial supervision","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The aim of this observational study is to characterize the urinary replication of BK polyomavirus (BKV) in kidney transplant recipients. Although BKV reactivation after transplantation is well established, the origin of the replicating virus remains uncertain. Current evidence suggests that BKV detected in recipients may originate either from the transplanted kidney (donor-derived) or from viral reactivation in the recipient. The evaluation of new biomarkers to predict BKV replication are needed.\n\nThis study seeks to address the following key questions:\n\n* Origin of the replicating virus: Is the BKV detected in the recipient identical to the virus originating from the donor kidney?\n* Host immune response and viral genotype: Is there an association between the recipient's immune response and the genotype of the replicating BKV?\n* Differences in immune response according to viral replication profile: Does the immune response differ between patients presenting isolated BKV viruria and those with both viruria and viremia?\n* Can new biomarkers help predict BKV replication and viremia?\n\nPatients will be grouped according to their BKV replication profile:\n\nGroup 1: patients with BKV viruria without viremia Group 2: patients with both BKV viruria and viremia Comparisons between these two groups will help identify whether different viral genotypes or immune responses are associated with systemic dissemination (viremia).\n\nKidney transplant recipients will be included if they present BKV viruria during their post-transplant follow-up. Additional blood samples will be collected during scheduled follow-up visits at the university hospital. These visits are part of routine clinical care, and no extra visits will be required specifically for the study.",[24,25,26,27,28,29,30,31,32],"Nephropathy","Opportunistic Viral Infection","Polyoma Virus Nephropathy","BK Nephropathy","BK Viremia; BKV DNAemia","BK Virus Infection","BK Polyomavirus","Immune Response","Neutralizing Antibodies",[34,35,36,37,38,39,40],"TTV","BK polyomavirus","neutralizing antibodies","ELISPOT BKV","genotype","miRNA BKV","urinary chimiokine","RECRUITING","2026-05-22",{"date":44,"type":45},"2026-05-27","ACTUAL",{"date":47,"type":45},"2026-03-11",{"date":49,"type":20},"2030-09-11",{"name":51,"class":52},"University Hospital, Grenoble","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":53},"100416261","characterization-of-antibacterial-antibodies-in-patients-with-cystic-fibrosis-100416261","NCT04700358","Characterization of Antibacterial Antibodies in Patients With Cystic Fibrosis","Identification and Characterization of Antibacterial Antibodies in Sera of Patients With Cystic Fibrosis","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to give consent\n* Normal vital signs including:\n* Blood pressure systolic value 150 - 100 mmHg, diastolic value \\\u003C 90 mmHg\n* Respiratory rate \\\u003C 20\u002Fmin\n* Oxygen saturation \\>92%\n* Heart rate 50 - 110\u002Fmin\n* Body temperature \\\u003C38°C\n\nExclusion Criteria:\n\n* Cytopenia (leukocytes \\\u003C 1.500\u002Fµl, thrombocytes \\\u003C 50.000\u002Fµl, Hemoglobin \\\u003C 12 g\u002Fdl)\n* Heart disease or pulmonary hypertension\n* Body weight \\\u003C50 kg (exclusion of blood sampling for B cell isolation)\n* Blood donation, larger blood loss and\u002For major surgery in the last 8 (male) or 12 (female) weeks\n* Any decline of the general state of health in the last 3 month including weight loss \\> 2kg, pulmonal exacerbation or increased impairment of pulmonary function (FEV1 \\\u003C 50%)",true,{"count":63,"type":20},75,"Most of the cystic fibrosis (CF) patients are or have been pulmonary colonized with bacteria such as Pseudomonas aeruginosa or Staphylococcus aureus. Aim of this study is to detect virulence factor neutralizing antibodies in the sera of the study population followed by B cell repertoire analyses to design B cell-derived neutralizing monoclonal antibodies. The functionality of neutralizing antibodies rests on inhibition of virulence factors by binding of crucial epitopes rather than merely the induction of opsonization. Focusing on patients with bacterial colonization\u002Fchronic infections or a history of an acute infection in the past, will increase the likelihood for identification of serum with neutralizing activity as in vivo antigen contact is a prerequisite for antibody development and maturation. Since virulence factors are essential for infection, dissemination and tissue damage, inhibition of these factors by developed neutralizing antibodies might contribute to a favorable outcome of life-threatening infections.",[66,32],"Pulmonary Cystic Fibrosis","2024-05-07",{"date":69,"type":45},"2024-05-08",{"date":71,"type":45},"2020-10-01",{"date":73,"type":20},"2027-12-31",{"name":75,"class":52},"University Hospital of Cologne"]